CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01911 CR HOLDINGS

Trading 03-03 09:39:22

3.900

-0.080

-2.01%

High4.000	Low3.910	Vol16.40K
Open3.980	D1 Closing3.980	Amplitude2.26%
Mkt Cap2.23B	Tradable Cap2.23B	Total Shares573.00M
T/O64.61K	T/O Rate0.00%	Tradable Shares573.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01911","market":"HK","secType":"STK","nameCN":"CR HOLDINGS","latestPrice":3.9,"timestamp":1772501914231,"preClose":3.98,"halted":0,"volume":16400,"delay":0,"changeRate":-0.02010050251256283,"floatShares":573000000,"shares":573000000,"eps":-0.349837,"marketStatus":"Trading","change":-0.08,"latestTime":"03-03 09:39:22","open":3.98,"high":4,"low":3.91,"amount":64612,"amplitude":0.022613,"askPrice":3.9,"askSize":11800,"bidPrice":3.88,"bidSize":9900,"shortable":3,"etf":0,"ttmEps":-0.077,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1772510400000},"marketStatusCode":2,"adr":0,"listingDate":1537977600000,"exchange":"SEHK","adjPreClose":3.98,"openAndCloseTimeList":[[1772501400000,1772510400000],[1772514000000,1772524800000]],"volumeRatio":0.314337,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01911/tweets","defaultTab":"tweets","newsList":[{"id":"2611190152","title":"Innovent Biologics Doses First Patient in Phase 3 Trial of Novel HER2 ADC for Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2611190152","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611190152?lang=en_us&edition=fundamental","pubTime":"2026-02-13 08:00","pubTimestamp":1770940820,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the initiation of a pivotal Phase 3 clinical study, HeriCare-Breast01, evaluating IBI354—a HER2 monoclonal antibody-camptothecin derivative conjugate —as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. The first participant has been successfully dosed in this study in China. IBI354 is also being investigated in another ongoing pivotal Phase 3 trial, HeriCare-Ovarian01. Early-stage studies have demonstrated a favorable safety and efficacy profile for IBI354, but the results of the current Phase 3 trial have not yet been presented and are anticipated in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7Y3cHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","01911","HK0000165453.HKD","LU2097828714.EUR","LU1969619763.USD","LU2488822045.USD","LU2097828631.EUR","LU2097828805.USD","LU2328871848.SGD","BK1147","LU2097828557.USD","LU0502904849.HKD","LU2242644610.SGD","LU2097828474.EUR","LU0455707207.USD","01801","BK1589"],"gpt_icon":0},{"id":"2610991047","title":"Individual investors are China Renaissance Holdings Limited's (HKG:1911) biggest owners and were rewarded after market cap rose by HK$298m last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2610991047","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610991047?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:36","pubTimestamp":1770856608,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by individual investors in China Renaissance Holdings indicates that they...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/individual-investors-are-china-renaissance-holdings-limiteds-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/individual-investors-are-china-renaissance-holdings-limiteds-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2609705575","title":"Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2609705575","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609705575?lang=en_us&edition=fundamental","pubTime":"2026-02-08 18:15","pubTimestamp":1770545735,"startTime":"0","endTime":"0","summary":"Feb 8 (Reuters) - Innovent Biologics Inc <1801.HK>::*INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY*INNOVENT BIOLOGICS - INNOVENT WI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nRSD8YHxbZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","BK1589","LU2097828474.EUR","LU1969619763.USD","LU2097828805.USD","BK1161","LU2488822045.USD","BK1147","01801","BK1583","LU2097828557.USD","LU2242644610.SGD","LU0455707207.USD","LU2097828714.EUR","LU2097828631.EUR","HK0000165453.HKD","01911","LU2328871848.SGD"],"gpt_icon":0},{"id":"2609757865","title":"Innovent Biologics and Eli Lilly Announce Global Oncology and Immunology Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2609757865","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609757865?lang=en_us&edition=fundamental","pubTime":"2026-02-08 18:05","pubTimestamp":1770545116,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced a strategic collaboration with Eli Lilly and Company to jointly develop novel medicines in the fields of oncology and immunology. This marks the seventh partnership between the two companies and aims to accelerate global development of Innovent's innovative pipeline. Under the agreement, Innovent will lead early-stage development through Phase 2 clinical trials in China, while Lilly will have exclusive rights to develop and commercialize these medicines outside Greater China. Innovent will receive a $350 million upfront payment and could earn up to $8.5 billion in milestone payments, as well as tiered royalties on sales outside Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nNDL59ms5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1161","LU0455707207.USD","LU2097828474.EUR","BK1147","LU2328871848.SGD","01801","HK0000165453.HKD","LU2097828631.EUR","BK1589","LU2097828805.USD","LU2097828557.USD","01911","LU2097828714.EUR","BK1583","LU0502904849.HKD","LU1969619763.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2608357471","title":"Innovent Biologics Reports 45% Year-Over-Year Growth in 2025 Product Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2608357471","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608357471?lang=en_us&edition=fundamental","pubTime":"2026-02-04 18:21","pubTimestamp":1770200503,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that its total product revenue for the full year of 2025 reached approximately RMB11.9 billion, reflecting a year-over-year growth of around 45%. In the fourth quarter of 2025, the company reported product revenue of approximately RMB3.3 billion, marking a strong year-over-year increase. The company also noted that it recognized inventory price adjustments in the fourth quarter for products previously distributed at original prices. This adjustment was primarily attributed to the inclusion of six new drugs in the 2026 National Reimbursement Drug List . The financial information provided is based on internal management records and has not been audited or reviewed by external auditors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL45qrJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","LU2097828631.EUR","HK0000165453.HKD","BK1147","LU2242644610.SGD","BK1583","LU1969619763.USD","01911","01801","LU2488822045.USD","LU2097828714.EUR","BK1589","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","BK1161","LU0502904849.HKD","LU2097828805.USD"],"gpt_icon":0},{"id":"2606069222","title":"FDA Grants Fast Track Designation to Innovent's IBI3003 for Relapsed or Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2606069222","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606069222?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:00","pubTimestamp":1769472021,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that its anti-GPRC5D/BCMA/CD3 trispecific antibody, IBI3003, has received Fast Track Designation from the U.S. Food and Drug Administration  for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The designation is intended to facilitate the development and expedite the review of IBI3003, which is currently undergoing Phase 1/2 clinical trials in China and Australia, with plans to initiate similar trials in the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL5fvCDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","BK1147","LU2097828805.USD","LU2097828474.EUR","LU2328871848.SGD","LU2242644610.SGD","HK0000165453.HKD","01801","LU2488822045.USD","LU1969619763.USD","BK1589","LU0455707207.USD","LU0502904849.HKD","LU2097828557.USD","LU2097828714.EUR","01911","BK1161","BK1583"],"gpt_icon":0},{"id":"2602311894","title":"Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602311894","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602311894?lang=en_us&edition=fundamental","pubTime":"2026-01-09 08:00","pubTimestamp":1767916821,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc., in collaboration with its partner Ollin Biosciences, has announced positive topline results from the randomized, head-to-head Phase 1b JADE clinical study. The study compared IBI324 , a next-generation VEGF/Ang2 bispecific antibody, to faricimab  in over 160 patients with diabetic macular edema  or wet age-related macular degeneration . According to the announcement, OLN324 demonstrated superior outcomes and is characterized by higher anti-Ang2 potency and a differentiated profile for first-line standard of care. Full results from the JADE study are scheduled to be presented at the Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026. Innovent and Ollin plan to advance OLN324 into global Phase 3 studies for both DME and wAMD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1BjwzH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU2097828557.USD","LU2097828474.EUR","LU2097828631.EUR","01911","01801","HK0000165453.HKD","LU0455707207.USD","BK1147","LU2097828714.EUR","LU2097828805.USD","BK1161","LU2328871848.SGD","LU2242644610.SGD","LU2488822045.USD","LU0502904849.HKD","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2601433466","title":"China Renaissance Holdings Insiders Made A Wise Decision By Selling CN¥7.5m Worth Of Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601433466","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601433466?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:51","pubTimestamp":1767829875,"startTime":"0","endTime":"0","summary":"While China Renaissance Holdings Limited ( HKG:1911 ) shareholders have enjoyed a good week with stock up 14%, they...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/china-renaissance-holdings-insiders-made-a-wise-decision-by-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/china-renaissance-holdings-insiders-made-a-wise-decision-by-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CN","01911","BK1147"],"gpt_icon":0},{"id":"2595877264","title":"China Renaissance - Distressed Assets Portfolio I Are Non-Performing Personal Consumer Debts Owed to Fuzhou Qifu Financing Guarantee","url":"https://stock-news.laohu8.com/highlight/detail?id=2595877264","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595877264?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y108S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2595772574","title":"China Renaissance - Unit Buys Distressed Assets Portfolio I for RMB277.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595772574?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y108S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2595772501","title":"China Renaissance Acquires Distressed Assets in Discloseable Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772501","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595772501?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189683,"startTime":"0","endTime":"0","summary":"China Renaissance Holdings Ltd. announced that its wholly-owned subsidiary entered into agreements to acquire two portfolios of distressed assets. The acquisitions, valued at approximately RMB277.1 million and RMB31.2 million respectively, are considered discloseable transactions under Hong Kong Listing Rules, requiring an announcement but not shareholders' approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Renaissance Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL7QXJ4v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","BK1147"],"gpt_icon":0},{"id":"2595274950","title":"Innovent Biologics Gains China Approval for TABOSUN and Sintilimab in Colon Cancer Neoadjuvant Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2595274950","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595274950?lang=en_us&edition=fundamental","pubTime":"2025-12-29 07:30","pubTimestamp":1766964633,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that China's National Medical Products Administration has approved the New Drug Application for TABOSUN  in combination with sintilimab as a neoadjuvant treatment for stage IIB-III resectable microsatellite instability-high  or mismatch repair deficient colon cancer. The approval is based on interim analysis from the NeoShot trial, which showed a pathological complete response rate of 82% among the first 50 patients treated, without significant safety risks compared to direct surgery.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nNDL2f1t1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1583","LU0455707207.USD","LU2097828631.EUR","LU2097828474.EUR","LU2097828805.USD","HK0000165453.HKD","LU2097828557.USD","LU2328871848.SGD","LU2097828714.EUR","BK1161","01801","BK1147","LU1969619763.USD","LU0502904849.HKD","BK1589","01911","LU2242644610.SGD"],"gpt_icon":0},{"id":"2594233216","title":"Innovent Biologics Wins NMPA Approval for First Domestic CTLA-4 Antibody TABOSUN in Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233216","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594233216?lang=en_us&edition=fundamental","pubTime":"2025-12-25 16:45","pubTimestamp":1766652331,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has received regulatory approval from China's National Medical Products Administration  for TABOSUN , the first domestic cytotoxic lymphocyte-associated antigen-4  monoclonal antibody. The approval is for use in combination with TYVYT  as a neoadjuvant treatment for patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient  colon cancer. This dual-immunotherapy regimen is the first and only approved globally for neoadjuvant treatment of colon cancer, addressing a significant unmet clinical need and offering a new therapeutic option for patients in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251225:nNDL681Kfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU2097828805.USD","BK1583","LU2097828557.USD","LU2097828714.EUR","HK0000165453.HKD","BK1161","LU2097828474.EUR","LU2328871848.SGD","LU2097828631.EUR","01801","LU0455707207.USD","BK1147","BK1589","LU0502904849.HKD","LU1969619763.USD","01911","LU2242644610.SGD"],"gpt_icon":0},{"id":"2592941037","title":"Innovent Biologics Publishes Landmark Phase 3 Mazdutide Diabetes Trials in Nature","url":"https://stock-news.laohu8.com/highlight/detail?id=2592941037","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592941037?lang=en_us&edition=fundamental","pubTime":"2025-12-18 08:00","pubTimestamp":1766016043,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the publication of results from two Phase 3 clinical studies  of mazdutide, a GLP-1/GCG dual receptor agonist, in Chinese adults with type 2 diabetes. The results were published as Accelerated Article Previews in Nature. Previously, the results of mazdutide’s Phase 3 weight loss clinical study  were published in The New England Journal of Medicine. Mazdutide is approved in China for glycemic control and weight management. Multiple additional studies and indication explorations for mazdutide are ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire  on December 18, 2025, and is solely responsibl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL6l1K4R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","BK1147","LU2097828805.USD","LU2097828474.EUR","LU2328871848.SGD","LU2242644610.SGD","HK0000165453.HKD","01801","LU2488822045.USD","LU1969619763.USD","BK1589","LU0455707207.USD","LU0502904849.HKD","LU2097828557.USD","LU2097828714.EUR","01911","BK1161","BK1583"],"gpt_icon":0},{"id":"2590554083","title":"Innovent Biologics Reports Mazdutide Achieves Significant Weight Loss in Chinese Adolescents with Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2590554083","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590554083?lang=en_us&edition=fundamental","pubTime":"2025-12-12 08:00","pubTimestamp":1765497619,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the results of a Phase 1b clinical study evaluating mazdutide, a dual GLP-1 and glucagon receptor agonist, in Chinese adolescents with obesity. The study met its primary endpoint, with participants receiving 4 mg and 6 mg doses of mazdutide achieving BMI reductions of 8.78% and 10.99%, and weight reductions of 7.72 kg and 8.65 kg, respectively, over 12 weeks. These outcomes were significantly greater than those observed in the placebo group. Mazdutide also showed favorable safety and tolerability, with no serious adverse events reported. Improvements were noted in multiple metabolic parameters. Based on these results, Innovent Biologics plans to initiate a Phase 3 registration clinical trial in adolescents with obesity or overweight in the near future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2Zl9Bl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU2097828631.EUR","BK1583","BK1161","LU0502904849.HKD","BK1589","LU2097828557.USD","LU2488822045.USD","LU0455707207.USD","01911","LU2242644610.SGD","LU1969619763.USD","BK1147","LU2328871848.SGD","LU2097828714.EUR","HK0000165453.HKD","LU2097828474.EUR","LU2097828805.USD"],"gpt_icon":0},{"id":"2590373878","title":"Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590373878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590373878?lang=en_us&edition=fundamental","pubTime":"2025-12-10 08:27","pubTimestamp":1765326446,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein  monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 , which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6WJy9c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","HK0000165453.HKD","LU2097828557.USD","LU2488822045.USD","LU2097828474.EUR","LU2097828631.EUR","LU2097828714.EUR","BK1147","LU0455707207.USD","LU1969619763.USD","BK1583","BK1161","01911","LU2242644610.SGD","LU2328871848.SGD","LU2097828805.USD","01801","BK1589"],"gpt_icon":0},{"id":"2590362883","title":"Innovent Biologics' PECONDLE Achieves Phase 3 Success for Moderate-to-Severe Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2590362883","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590362883?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:00","pubTimestamp":1765238427,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced that its self-developed recombinant anti-interleukin-23p19 subunit monoclonal antibody, PECONDLE , met both primary and key secondary efficacy endpoints in the Phase 3 CLEAR-2 study. The CLEAR-2 trial was a randomized withdrawal and retreatment study conducted in Chinese participants with moderate-to-severe plaque psoriasis. PECONDLE received market approval from the National Medical Products Administration  in November 2025 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The results of the Phase 3 study have already been announced.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLcdBYNS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01801","LU2097828714.EUR","BK1147","LU2488822045.USD","LU2097828474.EUR","LU2097828557.USD","LU1969619763.USD","LU2328871848.SGD","BK1583","BK1589","LU2097828805.USD","LU2242644610.SGD","LU0502904849.HKD","HK0000165453.HKD","LU0455707207.USD","01911","LU2097828631.EUR"],"gpt_icon":0},{"id":"2589802568","title":"Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802568","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802568?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:03","pubTimestamp":1765155800,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced initial results from the first-in-human Phase 1 clinical trial of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3 for the treatment of relapsed or refractory multiple myeloma. The data were presented in an oral session at the 2025 American Society of Hematology  Annual Meeting. IBI3003 demonstrated favorable tolerability and a manageable safety profile, with encouraging efficacy signals observed, particularly in high-risk patients, including those with extramedullary disease or prior exposure to anti-BCMA and/or anti-GPRC5D therapies. The ongoing Phase 1/2 clinical trial  is evaluating the safety, tolerability, and efficacy of IBI3003 in China and Australia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL2LlFwX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1161","BK1589","LU2328871848.SGD","01801","LU0502904849.HKD","LU2097828557.USD","LU2242644610.SGD","BK1583","LU2097828714.EUR","LU2097828805.USD","LU2097828474.EUR","BK1147","LU0455707207.USD","01911","LU2097828631.EUR","HK0000165453.HKD","LU1969619763.USD"],"gpt_icon":0},{"id":"2589871464","title":"Innovent Biologics Wins NRDL Inclusion for Seven Innovative Drugs in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2589871464","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589871464?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:06","pubTimestamp":1765101984,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL9rqL8K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","LU0455707207.USD","LU1969619763.USD","LU2097828631.EUR","HK0000165453.HKD","LU2328871848.SGD","LU2097828805.USD","LU2097828474.EUR","BK1161","LU2097828714.EUR","LU2242644610.SGD","BK1147","01801","LU0502904849.HKD","LU2488822045.USD","LU2097828557.USD","01911"],"gpt_icon":0},{"id":"2589042853","title":"Innovent Biologics and Takeda Launch $11.4 Billion Global Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2589042853","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589042853?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:39","pubTimestamp":1764891541,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has finalized a global strategic partnership with Takeda to accelerate the development and commercialization of next-generation immuno-oncology  and antibody-drug conjugate  therapies. The collaboration includes joint global development and U.S. co-commercialization of IBI363 , global rights outside Greater China for IBI343 , and an exclusive option for Takeda to license global rights to IBI3001  outside Greater China. Takeda will pay Innovent $1.2 billion upfront, including a $100 million equity investment, with total deal value reaching up to $11.4 billion through additional development, sales milestones, and potential royalties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9L5xZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU2097828714.EUR","01911","BK1147","LU1969619763.USD","LU2097828474.EUR","HK0000165453.HKD","LU0502904849.HKD","BK1161","LU2097828631.EUR","LU2097828805.USD","LU2242644610.SGD","LU2097828557.USD","BK1589","LU0455707207.USD","LU2328871848.SGD","LU2488822045.USD","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinarenaissance.com","stockEarnings":[{"period":"1week","weight":-0.1385},{"period":"1month","weight":0.0025},{"period":"3month","weight":-0.1532},{"period":"6month","weight":-0.4742},{"period":"1year","weight":0.0815},{"period":"ytd","weight":-0.0363}],"compareEarnings":[{"period":"1week","weight":-0.0377},{"period":"1month","weight":-0.0485},{"period":"3month","weight":-0.0013},{"period":"6month","weight":0.0283},{"period":"1year","weight":0.1359},{"period":"ytd","weight":0.0167}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"China Renaissance Holdings Ltd is a holding company that is primarily engaged in providing investment banking and investment management services. The Company operates in four segments. Investment Banking segment provides early to late stage financial advisory and mergers and acquisitions advisory services, equity underwriting, sales, trading, brokerage, research services and structured financial services. Investment Management segment provides fund and asset management and manages its own investments in funds. China Renaissance (CR) Securities segment provides investment banking and asset management business. Others segment mainly includes wealth management business and investment and management of own funds.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.099096},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.014364},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.030489},{"month":4,"riseRate":0.2,"avgChangeRate":-0.077146},{"month":5,"riseRate":0.2,"avgChangeRate":-0.049869},{"month":6,"riseRate":1,"avgChangeRate":0.143061},{"month":7,"riseRate":0.4,"avgChangeRate":0.051599},{"month":8,"riseRate":0.6,"avgChangeRate":0.100699},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.131486},{"month":10,"riseRate":0,"avgChangeRate":-0.130048},{"month":11,"riseRate":0.285714,"avgChangeRate":0.027229},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.035994}],"exchange":"SEHK","name":"CR HOLDINGS","nameEN":"CR HOLDINGS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CR HOLDINGS(01911) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CR HOLDINGS,01911,CR HOLDINGS股票,CR HOLDINGS股票老虎,CR HOLDINGS股票老虎国际,CR HOLDINGS行情,CR HOLDINGS股票行情,CR HOLDINGS股价,CR HOLDINGS股市,CR HOLDINGS股票价格,CR HOLDINGS股票交易,CR HOLDINGS股票购买,CR HOLDINGS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CR HOLDINGS(01911) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}